Calamos Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
Calamos Advisors's BMY Position: Q1 2026 in Review
Calamos Advisors opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 8,629 shares worth $523K. The stake represents ﹤0.01% of the portfolio and ranks #902 among its holdings. This is a return to the name: Calamos Advisors previously reported a position in BMY as recently as Q1 2025.
Calamos Advisors first reported a position in BMY in Q2 2013 and has held it in 49 quarters since. The position peaked at $95.4M in Q2 2022. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Calamos Advisors held 8,629 shares of Bristol-Myers Squibb worth $523K as of Q1 2026.
- Bristol-Myers Squibb was a new Calamos Advisors position in Q1 2026.
- Bristol-Myers Squibb made up ﹤0.01% of Calamos Advisors's portfolio in Q1 2026, its #902 holding.
- Calamos Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 49 quarters since.
- Calamos Advisors's Bristol-Myers Squibb position peaked at $95.4M in Q2 2022.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.